The U.S. Food and Drug Administration has granted approval for a new drug targeting the mutations that drive more than 90% of ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit discusses what she learned at the inaugural AACR Drug Discovery ...
The Pancreatic Cancer Action Network responds to FDA approval of Rasonque™ (daraxonrasib) for patients with previously ...
Since 2003, we have awarded 240 grants to 220 scientists at 78 institutions, with a total research investment of approximately $249 million, including the competitive Research Grants Program and ...
NEW — Congress is Listening – Keep Raising Your Voice! Pancreatic cancer advocates are making their voices heard – and Congress is listening. Because of advocates like you across the country, ...
Daraxonrasib is poised to become the new standard of care for previously treated metastatic pancreatic cancer after detailed results from a Phase III clinical trial were released at the American ...
Dr. Jill P. Smith is a clinician scientist and professor of medicine at Georgetown University and a member of the Lombardi Comprehensive Cancer Center. She also is a staff physician in ...
For the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma, more than 90% of tumors are thought to have a KRAS mutation. For decades, these mutations were considered “undruggable, ...
American Cancer Society’s Cancer Facts & Figures 2023, released today, reports that the five-year survival rate for pancreatic cancer is now 12%, an increase of one percentage point from last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results